Celgene Corp (CELG) 114.69 $CELG Look for Shares of

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Celgene Corp (CELG) 114.69 $CELG

Look for Shares of Celgene to Potentially Pullback after Yesterday's 1.45% Rise
Comtex SmarTrend(R) - Mon Aug 01, 12:02PM CDT
Celgene (NASDAQ:CELG) traded in a range yesterday that spanned from a low of $111.61 to a high of $115.02. Yesterday, the shares gained 1.5%, which took the trading range above the 3-day high of $112.43 on volume of 3.8 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
CELG: 114.69 (+2.50)

Company News for July 29, 2016
Zacks Equity Research - Zacks Investment Research - Fri Jul 29, 9:10AM CDT
Companies In The News are: CELG,MA,HOG,AMGN
HOG: 51.66 (-1.26), AMGN: 174.16 (+2.13), MA: 95.07 (-0.17), CELG: 114.69 (+2.50)

Celgene Rises 2.40% on Heavy Volume: Watch For Potential Pullback
Comtex SmarTrend(R) - Thu Jul 28, 11:52AM CDT
Celgene (NASDAQ:CELG) traded in a range yesterday that spanned from a low of $109.80 to a high of $111.70. Yesterday, the shares gained 2.4%, which took the trading range above the 3-day high of $108.84 on volume of 4.2 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
CELG: 114.69 (+2.50)

SmarTrend Watching for Potential Pullback in Shares of Celgene After 2.40% Gain
Comtex SmarTrend(R) - Thu Jul 28, 11:50AM CDT
Celgene (NASDAQ:CELG) traded in a range yesterday that spanned from a low of $109.80 to a high of $111.70. Yesterday, the shares gained 2.4%, which took the trading range above the 3-day high of $108.84 on volume of 4.2 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
CELG: 114.69 (+2.50)

Celgene (CELG) Tops Q2 Earnings & Revenues, Lifts View
Zacks Equity Research - Zacks Investment Research - Thu Jul 28, 11:11AM CDT
Celgene (CELG) reported better-than-expected second-quarter 2016 earnings and revenues; it once again raised the earnings outlook for 2016.
INVA: 13.04 (+0.17), FCSC: 1.02 (-0.07), ANIP: 61.06 (+0.46), CELG: 114.69 (+2.50)

Watch for Shares of Celgene (CELG) to Approach Resistance at $110.78
Comtex SmarTrend(R) - Thu Jul 28, 8:34AM CDT
Celgene (NASDAQ:CELG) has opened bullishly above the pivot of $107.50 today and has reached the first level of resistance at $109.45. Analysts will be watching for a cross of the next upside pivot targets of $110.78 and $114.06.
CELG: 114.69 (+2.50)

The Zacks Analyst Blog Highlights: Biogen, Gilead, AbbVie, Amgen and Celgene
Zacks Equity Research - Zacks Investment Research - Thu Jul 28, 8:30AM CDT
The Zacks Analyst Blog Highlights: Biogen, Gilead, AbbVie, Amgen and Celgene
BIIB: 301.83 (+11.90), GILD: 80.46 (+0.99), AMGN: 174.16 (+2.13), ABBV: 66.94 (+0.71), CELG: 114.69 (+2.50)

Celgene (CELG) Beats on Q2 Earnings and Revenues
Zacks Equity Research - Zacks Investment Research - Thu Jul 28, 8:17AM CDT
Celgene beat on second-quarter 2016 earnings and revenues.
CELG: 114.69 (+2.50)

Celgene Reports Second Quarter 2016 Operating and Financial Results
BusinessWire - Thu Jul 28, 6:30AM CDT
--- REVLIMID(R) Net Product Sales $1.7B in Q2:16; Increased 18% Y/Y
CELG: 114.69 (+2.50), CELGZ: 1.14 (-0.02)

Biotech Stock Roundup: Biogen Q2 Results Impress, Gilead HCV Franchise Under Pressure
Arpita Dutt - Zacks Investment Research - Wed Jul 27, 2:25PM CDT
With the second quarter earnings season in full swing, several biotech companies including Amgen (AMGN) will be reporting this week.
BIIB: 301.83 (+11.90), VRTX: 98.20 (+1.20), GILD: 80.46 (+0.99), ALXN: 133.50 (+4.90), AMGN: 174.16 (+2.13), ABBV: 66.94 (+0.71), CELG: 114.69 (+2.50)

Watch for Drug Stocks Earnings on Jul 28: BMY, CELG & More
Zacks Equity Research - Zacks Investment Research - Wed Jul 27, 8:47AM CDT
How will drug stocks Bristol-Myers, Celgene and others perform when they report Q2 results on Jul 28, before the opening bell?
AGEN: 5.65 (+0.10), BIIB: 301.83 (+11.90), ABT: 45.29 (+0.54), JNJ: 125.40 (+0.17), GILD: 80.46 (+0.99), ALXN: 133.50 (+4.90), ARIA: 9.71 (+0.20), BMY: 76.19 (+1.38), CELG: 114.69 (+2.50), NVS: 83.07 (-0.19)

Celgene and LYSARC Provide Update on the Phase III 'REMARC' Study of REVLIMID(R) Maintenance Treatment in Patients with Diffuse Large B-Cell Lymphoma Responding to First-Line R-CHOP Therapy
BusinessWire - Mon Jul 25, 3:30PM CDT
Celgene Corporation (NASDAQ: CELG) and the Lymphoma Study Association (LYSA) today announced that the Lymphoma Academic Research Organisation (LYSARC) reported initial data from a phase III, randomized, double-blind, international clinical study (REMARC). This investigational study evaluated maintenance therapy with REVLIMID(R) (lenalidomide) compared with placebo in diffuse large B-cell lymphoma (DLBCL) patients responding to first-line rituximab plus CHOP chemotherapy (R-CHOP) induction therapy. LYSARC sponsored the study under a Clinical Trial Agreement with Celgene.
CELG: 114.69 (+2.50), CELGZ: 1.14 (-0.02)

Celgene's Revlimid Gains EU Nod for Mantle Cell Lymphoma
Zacks Equity Research - Zacks Investment Research - Mon Jul 18, 5:45PM CDT
Celgene's (CELG) Revlimid gained label expansion in the EU; it can now be used for the treatment of adults with relapsed or refractory mantle cell lymphoma.
MACK: 5.82 (+0.02), INVA: 13.04 (+0.17), FCSC: 1.02 (-0.07), CELG: 114.69 (+2.50)

REVLIMID(R) (Lenalidomide) Approved by the European Commission for the Treatment of Relapsed/Refractory Patients with Mantle Cell Lymphoma
BusinessWire - Fri Jul 15, 1:00AM CDT
--Approval gives Celgene its first opportunity to support unmet needs of lymphoma patients across the European Union
CELG: 114.69 (+2.50), CELGZ: 1.14 (-0.02)

InvestorsObserver releases covered-call reports for Freeport-McMoRan, Intel, Agrium Incorporated, Caterpillar Inc. and Celgene
PR Newswire - Thu Jul 14, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for AGU, CAT, CELG, FCX, and INTC.
FCX: 12.48 (-0.48), AGU: 90.09 (-0.67), CAT: 81.95 (-0.81), INTC: 34.85 (-0.01), CELG: 114.69 (+2.50)

Stock Market News for July 07, 2016
Zacks Equity Research - Zacks Investment Research - Thu Jul 07, 9:10AM CDT
Benchmarks ended in the green on Wednesday after the FOMC minutes from June meeting showed that most of the Fed policymakers were in favor of keeping rates unchanged.
MDVN: 64.08 (+0.09), BIIB: 301.83 (+11.90), VRTX: 98.20 (+1.20), GILD: 80.46 (+0.99), UNH: 143.51 (+0.31), MRK: 58.66 (unch), ALXN: 133.50 (+4.90), XOM: 85.86 (-3.09), CVX: 99.11 (-3.37), REGN: 434.00 (+8.88), CELG: 114.69 (+2.50)

Biotechnology Equities Under the Scanner - Exelixis, Novavax, Celgene, and Ariad Pharma
PR Newswire - Thu Jul 07, 7:00AM CDT
On Wednesday, July 06, 2016, the NASDAQ Composite ended the trading session at 4,859.16, up 0.75%; the Dow Jones Industrial Average edged 0.44% higher, to finish at 17,918.62; and the S&P 500 closed at 2,099.73, up 0.54%. The gains were broad based as eight out of nine sectors ended the session in positive. Stock-Callers.com has initiated coverage on the following equities: Exelixis Inc. (NASDAQ: EXEL), Novavax Inc. (NASDAQ: NVAX), Celgene Corporation (NASDAQ: CELG), and Ariad Pharmaceuticals Inc. (NASDAQ: ARIA). Learn more about these stocks by accessing their free notes at:
NVAX: 7.35 (+0.03), ARIA: 9.71 (+0.20), CELG: 114.69 (+2.50), EXEL: 9.27 (+0.09), CELGZ: 1.14 (-0.02)

Watch for Celgene to Potentially Pullback After Gaining 3.49% Yesterday
Comtex SmarTrend(R) - Wed Jul 06, 11:56AM CDT
Celgene (NASDAQ:CELG) traded in a range yesterday that spanned from a low of $100.13 to a high of $104.94. Yesterday, the shares gained 3.5%, which took the trading range above the 3-day high of $101.39 on volume of 3.9 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
CELG: 114.69 (+2.50)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Voltage Energy's Microgrid Launches at RE+ 2026

Updated Category News Views 147

Voltage Energy Unveils New Power Systems In the swirling chaos of energy innovation, Voltage Energy is trying to carve its path at the heart of RE+ 2026. Out in Las Vegas, amidst the buzz of renewable energy tech, they introduced their Microgrid System (MGS) along with two new electrical balance of system (EBOS) products—the Load Break Disconnect Box (LBD) and Combiner...

Continue Reading
CD Rates Offer Stillness as Stocks and Gold Wobble

Updated Category News Views 59

November has delivered the sort of tape that makes a supposedly diversified portfolio feel like a leaky boat. Stocks fell sharply, gold slid to a one-year low after record highs as recently as January, and Treasuries have not provided the dependable ballast many investors expected. When inflation worries and federal-debt concerns shove yields higher, bond prices can drop...

Continue Reading
Iberostar's Grand Move: Opening in Zanzibar

Updated Category News Views 114

The Resort That Takes Your Breath Away Here we have Iberostar, boldly wading into the azure waters of the Indian Ocean, planting its flag on the sandy beaches of Zanzibar. This isn’t just another notch on the resort’s belt—it’s their first time setting up shop in East Africa, a move ripe with promise and adventure both. A Suite So Sweet 358 suites, mind you. Each...

Continue Reading
Chaos Zero Nightmare's Award Is a Useful Signal for Games

Updated Category News Views 19

A story award can be easy to sneer at until a live-service game earns one across three markets. Smilegate's Chaos Zero Nightmare, a dark fantasy roguelike RPG developed by Super Creative, was named Best Story in Google Play's Best of 2026 awards for Taiwan, Hong Kong and Macau. That is not a sales figure, not a profit disclosure, and certainly not proof that a hit has...

Continue Reading
Inhibrx Ewing Data Gives Ozekibart a Real Clinical Signal

Updated Category News Views 131

Numbers this lopsided in relapsed Ewing sarcoma make me sit up straight, even after years of watching oncology releases try to turn every blip into a brass band. Inhibrx has reported updated Phase 1/2 data for ozekibart, paired with irinotecan and temozolomide, that look genuinely notable in a disease where patients have very few good cards left to play. That matters...

Continue Reading
Onward Therapeutics Secures $28M to Bolster Oncology R&D

Updated Category News Views 76

Cashing In to Conquer Cancer In the risk-laden world of biotech, Onward Therapeutics has just bagged a hefty NT$900 million—roughly US$28 million—from its Series B financing. That's not pocket change and speaks to the level of confidence their backers have, even as they plant their global headquarters firmly in Taipei since relocating from Switzerland. A Deep Dive...

Continue Reading
Philadelphia Firm Targets 100 Toys for Children This Holiday

Updated Category News Views 139

A hundred unopened toys can look modest on paper, yet that is exactly why this Philadelphia effort lands differently than the usual chest-thumping corporate charity chatter. van der Veen, Hartshorn & Levin has set a clear holiday target: collect 100 new, unwrapped toys for children in the Philadelphia area through the U.S. Marine Corps Reserve Toys for Tots program. No...

Continue Reading
LAFC Turns Empty Seats Into an AI Test Case for Sports

Updated Category News Views 72

Empty seats are a lousy kind of inventory A vacant stadium seat is perishable inventory with the clock screaming at it. LAFC and AccelerAI have aimed their first co-developed AI project at that unglamorous but important problem: getting more ticket holders through the gate without simply hacking prices down at the last minute. That is a far more sensible use of artificial...

Continue Reading
Benicia's Bold Move to Streamline Permitting Pays Off

Updated Category News Views 147

Award-Winning Innovation from Benicia Benicia, California, shoots ahead of the pack by scooping up a highly coveted Helen Putnam Award for Excellence. Why? They chopped down bureaucracy like a lumberjack with a new ax by ushering in a digital revolution for their permitting process. Make no mistake, folks, this ain’t just a pat on the back—it's a blueprint for cities...

Continue Reading
Apani Adds Kelsun Assets to Its Natural Fiber Platform

Updated Category News Views 141

A materials deal with more chemistry than chest-thumping Seaweed and cotton have landed under one roof, which is a lot more interesting than another apparel brand slapping a green label on ordinary fabric. Apani said November 17 it acquired the assets of Keel Labs, bringing Keel's seaweed-based Kelsun fiber alongside Apani's enhanced cotton-cellulose filament technology....

Continue Reading

Top 5 Most Recently Viewed Articles

Trinseo Announces New Dividend Amid Strategic Changes Ahead

Updated Category News Views 225

Trinseo Approves Dividend for Shareholders Trinseo (NYSE: TSE), a prominent provider of specialty material solutions, has recently announced a quarterly dividend approved by its Board of Directors. The dividend declared stands at $0.01 per share, set to be distributed on a future date, offering a slight financial incentive for shareholders. To be eligible, shareholders...

Continue Reading
2026 Mighty 25: Celebrating Military Community Leaders

Updated Category News Views 26

A Spotlight on Unsung Heroes Tampa, Florida, just got a little mightier as We Are The Mighty rolls out the red carpet for the 2026 Mighty 25. This annual roll call, backed by CareSource Military & Veterans™, shines a light on veterans, military spouses, creators, entrepreneurs, and change agents defying the status quo. They are redefining impact across the military...

Continue Reading
Rubrik Inc Soars as Earnings Beat Expectations

Updated Category News Views 238

Rubrik Inc's Recent Stock Surge Rubrik, Inc. (NYSE: RBRK) has recently captured the attention of the market as its shares have risen over 20% following an impressive report of fourth-quarter earnings. The company exceeded expectations in both profitability and revenue, which undoubtedly prompted a wave of investor optimism. Financial Performance Highlights For the latest...

Continue Reading
Sanofi’s Amlitelimab Achieves Key Study Goals for Eczema Treatment

Updated Category News Views 284

Sanofi’s Amlitelimab Revolutionizes Atopic Dermatitis Treatment In an exciting development for patients suffering from atopic dermatitis, Sanofi's amlitelimab has met all primary and key secondary endpoints in the pivotal COAST 1 phase 3 study, targeting both adults and adolescents. This innovative medication demonstrated meaningful efficacy in terms of skin clearance...

Continue Reading
Alphamin Resources Corp: Board Changes and Future Outlook

Updated Category News Views 168

Leadership Changes at Alphamin Resources Corp Alphamin Resources Corp., a prominent player in the mining sector, recently shared significant news regarding its board of directors. The company announced the resignation of Mr. Rudolf Pretorius as a director. This change marks a pivotal moment in the company’s leadership structure, as Mr. Pretorius had been with the board...

Continue Reading